In addition, we tested sensitivity of two cell lines representative of Ph-like ALL, both carrying CRLF2 translocations but with different activating JAK2 mutations, for their sensitivity to the JAK2 kinase inhibitor ruxolitinib (Jakafi®). Here, CRLF2 is linked to acute lymphoblastic leukemia.